Literature DB >> 17522858

Prospective comparison of two gamma probes for intraoperative detection of 18F-FDG: in vitro assessment and clinical evaluation in differentiated thyroid cancer patients with iodine-negative recurrence.

Chantal Curtet1, Thomas Carlier, Eric Mirallié, Caroline Bodet-Milin, Caroline Rousseau, Jacques Barbet, Francoise Kraeber-Bodéré.   

Abstract

PURPOSE: This study was aimed at evaluating the spatial resolution and sensitivity of two hand-held gamma probes. Radioguided surgery was tested in seven patients with iodine-negative differentiated thyroid cancer (DTC) recurrence using (18)F-FDG PET.
METHODS: Two gamma probes were evaluated: Clerad's GammaSup with a collimated CsI(Tl) scintillator and Novelec's Modelo2 with a BGO scintillator. Five measurement tests were performed following the NEMA guidelines (NU3-2004). Radioguided surgery was performed in patients with recurrent DTC and abnormal (18)F-FDG uptake on preoperative (18)F-FDG PET images. Patients were injected with rTSH 2 days before surgery. A mean activity of 211 MBq of (18)F-FDG was injected 60 min before surgery. In vivo and ex vivo counts were recorded for suspected tumours and normal tissue.
RESULTS: Spatial resolution was higher with the CsI(Tl) than with the BGO detector: 20.2-40.6 mm vs 20.6-55.3 mm from 0 to 20 mm depth. Sensitivity in air and water and through side shielding was higher for BGO but the signal-to-noise ratio was 88 and 22 with the BGO compared to 131 and 76 with the CsI(Tl) at 10 and 30 mm depth. Median in vivo SNR (tumour/non-tumour ratio) was 1.8 with both the BGO and the CsI(Tl) detector, while ex vivo ratios of 2.3 and 2.1, respectively, were obtained. Radioguided surgery allowed detection of all of the tumours identified by (18)F-FDG PET images.
CONCLUSION: This study demonstrated the feasibility of high-energy photon detection with a conventional scintillator equipped with a collimator. The CsI(TI) probe detected more true events from background than did the BGO detector during surgery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17522858     DOI: 10.1007/s00259-007-0393-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  18 in total

Review 1.  The intraoperative gamma probe: basic principles and choices available.

Authors:  P Zanzonico; S Heller
Journal:  Semin Nucl Med       Date:  2000-01       Impact factor: 4.446

2.  18F-labeled fluorodeoxyglucose positron emission tomography-guided surgery for recurrent colorectal cancer: a feasibility study.

Authors:  E E Zervos; D C Desai; L R DePalatis; D Soble; E W Martin
Journal:  J Surg Res       Date:  2001-05-01       Impact factor: 2.192

3.  Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes.

Authors:  U Veronesi; G Paganelli; V Galimberti; G Viale; S Zurrida; M Bedoni; A Costa; C de Cicco; J G Geraghty; A Luini; V Sacchini; P Veronesi
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

4.  Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.

Authors:  A Frilling; K Tecklenborg; R Görges; F Weber; M Clausen; E C Broelsch
Journal:  Ann Surg       Date:  2001-12       Impact factor: 12.969

5.  Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer.

Authors:  L Hooft; O S Hoekstra; W Devillé; P Lips; G J Teule; M Boers; M W van Tulder
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

6.  [18F]fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase i expression in the primary tumor.

Authors:  L Hooft; A A M van der Veldt; P J van Diest; O S Hoekstra; J Berkhof; G J J Teule; C F M Molthoff
Journal:  J Clin Endocrinol Metab       Date:  2004-10-27       Impact factor: 5.958

7.  Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy.

Authors:  B O Helal; P Merlet; M E Toubert; B Franc; C Schvartz; H Gauthier-Koelesnikov; A Prigent; A Syrota
Journal:  J Nucl Med       Date:  2001-10       Impact factor: 10.057

8.  Dual-detector probe for surgical tumor staging.

Authors:  T S Hickernell; H B Barber; H H Barrett; J M Woolfenden
Journal:  J Nucl Med       Date:  1988-06       Impact factor: 10.057

9.  Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer.

Authors:  P Peltier; C Curtet; J F Chatal; J M Le Doussal; G Daniel; G Aillet; A Gruaz-Guyon; J Barbet; M Delaage
Journal:  J Nucl Med       Date:  1993-08       Impact factor: 10.057

10.  Intraoperative beta probe: a device for detecting tissue labeled with positron or electron emitting isotopes during surgery.

Authors:  F Daghighian; J C Mazziotta; E J Hoffman; P Shenderov; B Eshaghian; S Siegel; M E Phelps
Journal:  Med Phys       Date:  1994-01       Impact factor: 4.071

View more
  9 in total

1.  Comprehensive evaluation of occupational radiation exposure to intraoperative and perioperative personnel from 18F-FDG radioguided surgical procedures.

Authors:  Stephen P Povoski; Ismet Sarikaya; William C White; Steven G Marsh; Nathan C Hall; George H Hinkle; Edward W Martin; Michael V Knopp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-10       Impact factor: 9.236

Review 2.  Assessment of myocardial perfusion and function with PET and PET/CT.

Authors:  Mouaz H Al-Mallah; Arkadiusz Sitek; Stephen C Moore; Marcelo Di Carli; Sharmila Dorbala
Journal:  J Nucl Cardiol       Date:  2010-06       Impact factor: 5.952

3.  The use of intraoperative PET probe to resect metastatic melanoma.

Authors:  Grant O Lee; Nicholas G Costouros; Terry Groome; Mohammed Kashani-Sabet; Stanley P L Leong
Journal:  BMJ Case Rep       Date:  2010-07-15

Review 4.  A comprehensive overview of radioguided surgery using gamma detection probe technology.

Authors:  Stephen P Povoski; Ryan L Neff; Cathy M Mojzisik; David M O'Malley; George H Hinkle; Nathan C Hall; Douglas A Murrey; Michael V Knopp; Edward W Martin
Journal:  World J Surg Oncol       Date:  2009-01-27       Impact factor: 2.754

5.  Multimodal imaging and detection approach to 18F-FDG-directed surgery for patients with known or suspected malignancies: a comprehensive description of the specific methodology utilized in a single-institution cumulative retrospective experience.

Authors:  Stephen P Povoski; Nathan C Hall; Douglas A Murrey; Andrew Z Chow; Jay R Gaglani; Eamonn E Bahnson; Cathy M Mojzisik; Maureen P Kuhrt; Charles L Hitchcock; Michael V Knopp; Edward W Martin
Journal:  World J Surg Oncol       Date:  2011-11-23       Impact factor: 2.754

6.  Feasibility of a multimodal (18)F-FDG-directed lymph node surgical excisional biopsy approach for appropriate diagnostic tissue sampling in patients with suspected lymphoma.

Authors:  Stephen P Povoski; Nathan C Hall; Douglas A Murrey; Chadwick L Wright; Edward W Martin
Journal:  BMC Cancer       Date:  2015-05-08       Impact factor: 4.430

7.  Intra-operative use of PET probe for localization of FDG avid lesions.

Authors:  M A Molina; W J Goodwin; F L Moffat; A N Serafini; G N Sfakianakis; E Avisar
Journal:  Cancer Imaging       Date:  2009-09-29       Impact factor: 3.909

8.  18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and background tissues.

Authors:  Stephen P Povoski; Douglas A Murrey; Sabrina M Smith; Edward W Martin; Nathan C Hall
Journal:  BMC Cancer       Date:  2014-06-19       Impact factor: 4.430

9.  Comparison of two threshold detection criteria methodologies for determination of probe positivity for intraoperative in situ identification of presumed abnormal 18F-FDG-avid tissue sites during radioguided oncologic surgery.

Authors:  Gregg J Chapman; Stephen P Povoski; Nathan C Hall; Douglas A Murrey; Robert Lee; Edward W Martin
Journal:  BMC Cancer       Date:  2014-09-13       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.